AI assistant
Sending…
Nuvectis Pharma, Inc. — Director's Dealing 2023
Jun 16, 2023
33912_dirs_2023-06-16_14341d7a-b1f7-4612-a0cd-e88bf85288a0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2023-06-15
Reporting Person: Mosseri Marlio Charles (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-15 | Common Stock | P | 400 | $17.54 | Acquired | 2380576 | Direct |
| 2023-06-15 | Common Stock | P | 31724 | $17.71 | Acquired | 2412300 | Direct |
More from Nuvectis Pharma, Inc.
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Regulatory Filings
2026
Feb 23
Capital/Financing Update
2026
Feb 13
Earnings Release
2026
Feb 11
Annual Report
2026
Feb 11
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9